
ArtiQ is an AI-first software company focused on optimizing clinical trials and enhancing diagnostic processes in healthcare, particularly for respiratory conditions. Their solutions, such as ArtiQ.PFT, ArtiQ.QC, and ArtiQ.RBM, leverage artificial intelligence to support medical professionals in diagnosis and improve data quality and efficiency in clinical research for pharmaceutical companies. Founded in 2019 after extensive research at the University Hospital in Leuven, ArtiQ aims to integrate AI into daily medical practice for better patient outcomes. In April 2024, ArtiQ joined forces with Clario, a healthcare research and technology company, to expand its global reach. The company holds ISO 13485 certification and its ArtiQ.PFT software is CE marked.

ArtiQ is an AI-first software company focused on optimizing clinical trials and enhancing diagnostic processes in healthcare, particularly for respiratory conditions. Their solutions, such as ArtiQ.PFT, ArtiQ.QC, and ArtiQ.RBM, leverage artificial intelligence to support medical professionals in diagnosis and improve data quality and efficiency in clinical research for pharmaceutical companies. Founded in 2019 after extensive research at the University Hospital in Leuven, ArtiQ aims to integrate AI into daily medical practice for better patient outcomes. In April 2024, ArtiQ joined forces with Clario, a healthcare research and technology company, to expand its global reach. The company holds ISO 13485 certification and its ArtiQ.PFT software is CE marked.
Founded: 2019
Focus: AI software for pulmonary function test interpretation and QC
Regulatory status: ISO 13485 certified; ArtiQ.PFT CE marked (MDR/Class IIa)
Exit / M&A: Acquired by Clario (April 2024)
Seed funding: €1M seed round (June 2019)
Respiratory diagnostics and clinical trial data quality for pharmaceutical research.
2019
Medical software / Healthtech
€1,000,000
Named investors also include University Hospitals Leuven and a private investor